Risk factors and clinical prognosis after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100052022

Enrollment

Unknown

Registered

2021-10-14

Start date

2021-10-31

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancies

Interventions

Allogeneic hematopoietic stem cell transplantation group:No

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. patients or their legal representatives sign informed consent prior to the commencement of clinical study; 2. Age 15-60 years; 3. AML patients receiving allogeneic hematopoietic stem cell transplantation from peripheral blood stem cells; 4. No major organ dysfunction.

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver and kidney damage (alanine aminotransferase > 2.5 times of the upper normal limit, serum creatinine > 1.5 times of the upper normal limit), cardiopulmonary dysfunction (cardiac function NYHA III/IV, cardiac ejection fraction 2; 4. Patients with secondary tumor; 5. Patients who cannot independently choose to enter or exit clinical trials due to serious central nervous system disease or mental disease.

Design outcomes

Primary

Measure	Time frame
Overall survival;Non-relapse mortality;Relapse;	—

Countries

China

Contacts

Public ContactHuang He

The First Affiliated Hospital of Medical College of Zhejiang University

hehuangyu@126.com+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026